COO
HealthcareThe Cooper Companies, Inc. · Medical - Instruments & Supplies · $12B
What is The Cooper Companies, Inc.?
The Cooper Companies operates across two distinct healthcare segments — contact lenses and women's health — serving patients and clinicians in markets around the world. Headquartered in San Ramon, California, the company has built a broad commercial footprint across the Americas, Europe, and Asia Pacific.
CooperVision develops and markets a wide range of contact lenses, including spherical, toric, and multifocal designs that address conditions such as astigmatism, presbyopia, and myopia. CooperSurgical focuses on family and women's health, offering medical devices, fertility consumables and services, genomics, diagnostics, and contraception products. Together, the two segments give the company exposure to both the global vision care market and the growing fertility and women's health space.
The Cooper Companies was founded in 1983 and is headquartered in San Ramon, California.
- Spherical, toric, and multifocal contact lenses for vision correction
- Fertility consumables, equipment, and embryo options
- Preimplantation genetic testing services
- Surgical and office products including PARAGARD and uterine manipulators
- Point-of-care diagnostics and contraception solutions
Is COO a Good Stock to Buy?
UQS Score rates COO as Below Average overall.
The most constructive elements of COO's profile sit in its Valuation and Risk pillars, both of which register more favorably than its other dimensions. The Valuation pillar carries a Good label, suggesting the stock is not trading at a significant premium relative to its fundamentals — a meaningful consideration given the broader healthcare sector's often elevated pricing.
The Quality and Growth pillars both register as Weak, pointing to challenges in profitability metrics and near-term expansion momentum. These are the primary drags on the composite score and warrant careful attention from investors evaluating long-term compounding potential.
Pro members can see the exact pillar breakdown and the underlying financial metrics driving each score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does COO pay dividends?
No — The Cooper Companies, Inc. does not currently pay a dividend.
The Cooper Companies does not currently pay a dividend. For a company operating across capital-intensive medical device and fertility services markets, retained earnings are typically directed toward product development, acquisitions, and geographic expansion rather than shareholder distributions. Investors seeking income from this position would need to look elsewhere.
When does COO report earnings?
The Cooper Companies reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Given the Weak ratings on both Quality and Growth pillars, recent reporting periods appear to reflect pressure on profitability and revenue expansion relative to sector peers. The Neutral Risk rating suggests the balance sheet and operational stability have not deteriorated to a critical level.
For the most recent quarter's results and forward guidance, visit The Cooper Companies' investor relations page directly.
COO Price History
-31.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in The Cooper Companies, Inc.?
Based on The Cooper Companies, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
COO Long-term Outlook
The combination of Weak Growth and Weak Quality pillars suggests the near-term fundamental trajectory faces meaningful headwinds. The Neutral Risk profile provides some stability, but without stronger quality or growth signals, the path to score improvement depends heavily on execution in both the contact lens and women's health segments. The Good Valuation label does offer a degree of downside cushion relative to peers, which may matter if operating conditions improve.
Growth drivers
- Expanding global demand for specialty contact lenses, particularly myopia management products
- Growing fertility services market driven by demographic and societal trends
- Geographic expansion across Asia Pacific and emerging markets
Key risks
- Sustained weakness in quality metrics could pressure long-term compounding
- Integration and execution risk across two distinct business segments
- Competitive intensity in both vision care and women's health from larger, better-capitalized peers
COO vs Peers
The Cooper Companies competes across two healthcare niches, facing different rivals in vision care and women's health.
Straumann focuses primarily on dental solutions rather than vision or women's health, but competes for healthcare capital allocation among diversified medical device investors.
Hologic is a direct competitor in women's health diagnostics and surgical products, with a more concentrated focus on that segment than Cooper's dual-segment model.
Baxter operates across a broader range of hospital and renal care products, overlapping with Cooper in the medical device supply chain but not in contact lenses or fertility.
Frequently Asked Questions
What does The Cooper Companies do?
The Cooper Companies operates two segments: CooperVision, which makes contact lenses for conditions like astigmatism and presbyopia, and CooperSurgical, which provides medical devices, fertility services, genomics, and contraception products to healthcare professionals and patients worldwide.
Does COO pay dividends?
No, The Cooper Companies does not currently pay a dividend. The company appears to prioritize reinvesting capital into its two operating segments — contact lenses and women's health — rather than returning cash to shareholders through distributions.
When does COO report earnings?
The Cooper Companies follows a standard quarterly earnings cadence for US-listed companies. For exact reporting dates and the most recent results, check the investor relations section of the company's official website.
Is COO a good stock to buy?
UQS Score rates COO as Below Average, driven by Weak Quality and Growth pillar scores. The Valuation pillar carries a Good label, which provides some relative comfort on pricing, but the overall profile suggests caution. Pro members can view the complete pillar breakdown to form their own assessment.
Is COO overvalued?
The UQS Valuation pillar for COO is rated Good, suggesting the stock is not significantly overpriced relative to its fundamentals. However, valuation alone does not determine investment merit — the Weak Quality and Growth scores are important context for any valuation judgment.
How does COO compare to its competitors?
COO competes with companies like Hologic in women's health and faces broader medical device competition from firms like Baxter International. Its dual-segment structure differentiates it, but the Below Average UQS Score suggests it currently lags on quality and growth relative to the broader healthcare landscape.
What is COO's market cap bracket?
The Cooper Companies is classified as a large-cap stock, placing it among the larger publicly traded companies in the healthcare sector by market value.
Who founded The Cooper Companies?
The Cooper Companies was founded in 1983. Detailed founding history, including the names of original founders, is publicly available through the company's official corporate history and investor relations materials.
Is COO a long-term quality investment?
As a long-term quality indicator, COO's current UQS profile raises questions. The Weak Quality and Growth pillars suggest the business has not yet demonstrated the durable profitability and expansion characteristics typically associated with high-quality long-term compounders. The Neutral Risk and Good Valuation scores provide partial offsets.
What is the main competitive advantage of The Cooper Companies?
The Cooper Companies benefits from its dual-segment structure, combining a global contact lens business with a growing women's health and fertility platform. The UQS Moat pillar is rated Neutral, suggesting some competitive positioning but not a dominant structural advantage relative to sector peers.
What sector does COO belong to?
The Cooper Companies operates in the Healthcare sector, spanning medical devices through its contact lens and surgical product lines, and healthcare services through its fertility and genomics offerings.
Is COO a growth stock or value stock?
Based on the UQS pillar profile, COO does not fit neatly into either category. The Growth pillar is rated Weak, making a growth-stock classification difficult to support. The Good Valuation label gives it some value-oriented characteristics, though the overall Below Average score tempers that framing.
Unlock Full COO Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓See the exact UQS Score and all five pillar ratings
- ✓View the underlying financial metrics driving each score
- ✓Compare COO against sector peers on quality and growth
- ✓Access the complete valuation and risk breakdown
- ✓Track score changes as new earnings data arrives
Pro Analysis
COO — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 45.5 | 40.7 | 42.0 | 38.7 | 43.7 | 70.6 | 0.0 |
| May 22, 2026 | 45.5 | 40.7 | 42.0 | 38.7 | 43.7 | 70.4 | -0.2 |
| May 21, 2026 | 45.7 | 40.7 | 42.0 | 38.7 | 43.7 | 71.3 | 0.0 |
| May 20, 2026 | 45.7 | 40.7 | 42.0 | 38.7 | 43.7 | 71.5 | 0.0 |
| May 19, 2026 | 45.7 | 40.7 | 42.0 | 38.7 | 43.7 | 71.8 | -0.2 |
| May 16, 2026 | 45.9 | 40.7 | 42.0 | 38.7 | 43.7 | 72.7 | +0.1 |
| May 15, 2026 | 45.8 | 40.7 | 42.0 | 38.7 | 43.7 | 72.2 | -0.1 |
| May 14, 2026 | 45.9 | 40.7 | 42.0 | 38.7 | 43.7 | 72.8 | +0.1 |
| May 13, 2026 | 45.8 | 40.7 | 42.0 | 38.7 | 43.7 | 72.5 | -0.1 |
| May 12, 2026 | 45.9 | 40.7 | 42.0 | 38.7 | 43.7 | 73.1 | +0.1 |
COO — Pillar Breakdown
Quality
— 40.7/100 (25%)The Cooper Companies, Inc. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 38.7/100 (20%)The Cooper Companies, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 43.7/100 (15%)The Cooper Companies, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 72.4/100 (15%)The Cooper Companies, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 42/100 (25%)The Cooper Companies, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for COO.
Score Composition
Financial Data
More Stock Analysis
How is the COO UQS Score Calculated?
The UQS (Unified Quality Score) for The Cooper Companies, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses The Cooper Companies, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether The Cooper Companies, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.